Stock Detail
SANTARUS INC
Drug Manufacturers Other
SNTS @ Yahoo Finance | SNTS Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $2.73 | $2.80 | $-0.07 | -2.50% | 0.00 | $2.80 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $2.75 | $2.72 | 225,801 | 166.18M | 320,203 | 248.18 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 2.83 | 2.78 | 2.75 | 2.70 | 2.67 |
Stock Profile
Santarus, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products for the prevention and treatment of gastrointestinal diseases and disorders. It offers ZEGERID Powder for Oral Suspension 20 mg, an immediate-release formulation of the proton pump inhibitor omeprazole. This product is approved by the U.S. Food and Drug Administration (FDA) for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease, treatment and maintenance of healing of erosive esophagitis, and treatment of duodenal ulcers. The company also offers ZEGERID Powder for Oral Suspension 40 mg, approved by the FDA for the treatment of gastric ulcers and the reduction of risk of upper gastrointestinal bleeding in critically ill patients. ZEGERID Powder for Oral Suspension is marketed in the U.S. by Santarus and its co-promotion partner, Otsuka America Pharmaceutical, Inc. In addition, Santarus is developing ZEGERID Chewable Tablets (40 mg and 20 mg) and ZEGERID Capsules for which it has submitted new drug applications. The company has strategic sublicense agreement with TAP Pharmaceutical Products, Inc. Santarus was formed in 1996 and was formerly known as TBG Pharmaceuticals, Inc. The company is headquartered in San Diego, California.